Company Filing History:

9 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 1997-2007

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7288655 - α v integrin receptor antagonists (2007-10-30),

2. 7262169 - Process for preparing peptide intermediates (2007-08-28),

3. 6515126 - Chemical synthesis of spirocyclic piperidines by double ring-closing metathesis (2003-02-04),

4. 6407255 - Chemical synthesis of 1,2,4-triazolinone derivative (2002-06-18),

5. 6297376 - Chemical synthesis of morpholine derivatives (2001-10-02),

6. 6130331 - Chemical synthesis of a chiral 1,4-oxazin-2-one (2000-10-10),

7. 6063931 - Process for synthesizing carbapenem side chain intermediates (2000-05-16),

8. 6060607 - Process for synthesizing carbapenem side chain intermediates (2000-05-09),

9. 6046325 - Chemical synthesis of 1,4-oxazin-2-ones (2000-04-04),

10. 5892082 - Process for the preparation of dimethyl titanocene (1999-04-06),

11. 5681959 - Chemical synthesis of azaindoles (1997-10-28),

12. 5668280 - Chemical synthesis of a chiral oxazinone (1997-09-16),

Title: Ian Frank Cottrell: Innovator in Pharmaceutical Chemistry

Introduction

Ian Frank Cottrell is a notable inventor based in Hertford, GB. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 12 patents. His work primarily focuses on the synthesis of compounds that have therapeutic applications.

Latest Patents

Among his latest patents, Cottrell has developed compounds related to the synthesis of αv integrin receptor antagonists. This invention pertains to the synthesis of intermediates for the preparation of compounds of formula (A), where n is 2 or 3, and various salt forms of these compounds. These compounds are particularly useful as αβ3 receptor antagonists. Additionally, he has worked on a process for preparing peptide intermediates, which is directed towards the improved synthesis of compounds of formula (I). This intermediate compound is useful in the synthesis of anticancer agents known as PSA conjugates.

Career Highlights

Cottrell has had a distinguished career, working with prominent companies in the pharmaceutical industry. He has been associated with Merck Sharp & Dohme Corporation and Merck & Company, Inc., where he has contributed to various innovative projects and research initiatives.

Collaborations

Throughout his career, Cottrell has collaborated with several esteemed professionals in the field. Notable coworkers include Michael Stewart Ashwood and David Hands, who have worked alongside him on various projects.

Conclusion

Ian Frank Cottrell's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a significant inventor in the industry. His work continues to impact the development of therapeutic agents, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com